Kesatuan Eropah - Malta - EMA (European Medicines Agency)

merck europe b.v. - cetrorelix (as acetate) - ovulation; ovulation induction - ormoni u analogi pitwitarji u ipotalamiċi - il-prevenzjoni ta 'l-ovulazzjoni prematura f'pazjenti li għaddejjin minn stimulazzjoni kkontrollata ta' l-ovarji, segwita minn tekniki riproduttivi ta 'ovo-pick-up u assistiti. fi provi kliniċi, cetrotide kien użat mal-menopawsa gonadotropin (hmg), iżda l-esperjenza limitata mal-rikombinanti follicule l-follikoli (fsh) tissuġġerixxi effiċjenza simili.

Kesatuan Eropah - Malta - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Kesatuan Eropah - Malta - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaċċini - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Kesatuan Eropah - Malta - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - sustanzi kontra l-emorraġija - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Kesatuan Eropah - Malta - EMA (European Medicines Agency)

laboratorios hipra s.a - virus ħaj tal-virus tal-herpes tal-ifrat imħallat b'ġenet doppju tip 1, razza ceddel: 106.3-107.3 ccid50 - immunoloġiċi - bhejjem - għal-immunizzazzjoni attiva tal-bhejjem mill-età ta 'tliet xhur kontra l-bovini virus herpes tat-tip 1 (bohv-1) biex jitnaqqsu s-sinjali kliniċi ta' infectious bovine rhinotracheitis (ibr) u l-eskrezzjoni tal-virus fil-qasam. il-bidu tal-immunità: 21 jum wara t-tlestija tal-iskema bażika tat-tilqim. tul ta 'żmien tal-immunità: 6 xhur wara t-tkomplija tal-iskema bażika tat-tilqim.

Kesatuan Eropah - Malta - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimikotiċi għal użu sistemiku - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Kesatuan Eropah - Malta - EMA (European Medicines Agency)

accord healthcare s.l.u. - caspofungin acetate - candidiasis; aspergillosis - antimikotiċi għal użu sistemiku - trattament ta ' kandidjasi invażiva f'pazjenti adulti jew pedjatriċi. trattament ta 'asperġillożi invażiva f'pazjenti adulti jew pedjatriċi li huma refrattorji jew intolleranti għal amphotericin b, formulazzjonijiet lipidi ta' amphotericin b u/jew itraconazole. ir-refrattorjetà hija definita bħala l-progressjoni tal-infezzjoni jew nuqqas ta 'titjib wara minimu ta' 7 ijiem ta 'dożi terapewtiċi preċedenti ta' terapija antifungali effettiva. it-terapija empirika għal infezzjonijiet fungali preżunti (bħal candida jew aspergillus) f'bid-deni, newtropeniċi febbri adulti jew pazjenti pedjatriċi.

Kesatuan Eropah - Malta - EMA (European Medicines Agency)

biogaran - clopidogrel (as hydrogen sulfate) - peripheral vascular diseases; stroke; myocardial infarction - aġenti antitrombotiċi - il-prevenzjoni ta ' avvenimenti aterotrombotiċi clopidogrel huwa indikat fl:pazjenti adulti li jbatu minn infart mijokardijaku (minn ftit jiem sa inqas minn 35 jum), puplesija iskemika (minn 7 ijiem sa inqas minn 6 xhur) jew mard arterjali periferali.

Kesatuan Eropah - Malta - EMA (European Medicines Agency)

archie samiel s.r.o. - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - aġenti antitrombotiċi - clopidogrel huwa indikat fl-adulti għall-prevenzjoni ta 'avvenimenti aterotrombotiċi f': pazjenti li jbatu minn infart mijokardijaku (minn ftit jiem sa inqas minn 35 jum), puplesija iskemika (minn 7 ijiem sa inqas minn 6 xhur) jew mard arterjali periferali;il-pazjenti li jbatu mis-sindromu koronarju akut:mhux-st segment tal-elevazzjoni tal-sindromu koronarju akut (anġina instabbli jew mhux tal-mewġa q-infart mijokardiku), li jinkludu pazjenti fi proċess li titpoġġa stent wara intervent koronarju perkutanju, flimkien ma ' acetylsalicylic acid (asa);st segment tal-elevazzjoni tal-infart mijokardijaku akut, flimkien ma ' asa f'medikament pazjenti kkurati b'eliġibbli għat-terapija trombolitika.

Kesatuan Eropah - Malta - EMA (European Medicines Agency)

sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - aġenti antitrombotiċi - koronarju akut syndromemyocardial mijokardijaku.